# Dual PD-1 and JAK2 Inhibition in Hematological Malignancies

> **NCT04016116** · PHASE2 · WITHDRAWN · sponsor: **NYU Langone Health**

## Conditions studied

- Cancer
- Hematological Malignancy

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT04016116
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-12
- **Primary completion:** 2020-12
- **Final completion:** 2021-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI left the institution
- **Last updated:** 2020-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04016116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04016116, "Dual PD-1 and JAK2 Inhibition in Hematological Malignancies". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04016116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*